REG - Oxford BioDynamics - PDMR Dealing / Grant of Share Options
10/11/2025 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251110:nRSJ8394Ga&default-theme=true
RNS Number : 8394G Oxford BioDynamics PLC 10 November 2025
10 November
2025
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing / Grant of Share Options
Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical
diagnostics company bringing specific and sensitive tests to the practice of
medicine based on its EpiSwitch® 3D genomics platform, announces that it has
today granted a total of 170,000,000 options over its ordinary shares of 0.1
pence each ("Ordinary Shares"), to Group employees and advisers, including
certain directors and PDMRs of the Company, as outlined in the table below.
The options were granted under the Company's 2016 Employee and Non-Employee
Share Option Plans with an exercise price of 0.61p per share, representing a
premium of 100% over the closing share price on 7 November 2025, the business
day immediately preceding the grant of the options.
119,000,000 options granted to directors and PDMRs will vest monthly in 24
equal tranches to 10 November 2027.
51,000,000 options will vest in three tranches: 20% will vest immediately and
will be exercisable from six months after the date of grant; 40% will vest and
become exercisable on 10 November 2026; and 40% will vest and become
exercisable on 10 November 2027.
Vested options will remain exercisable up to and including the tenth
anniversary of the date of grant.
The grants made to directors and PDMRs of the Company were as follows:
New options granted Total number of options over Ordinary Shares Ordinary Shares held*
Number % of current issued share capital
Iain Ross, Executive Chairman 44,000,000 140,000,000 23,333,333 0.54
Alexandre Akoulitchev, Chief Scientific Officer 15,000,000 34,596,131 14,228,962 0.33
David Blum, SVP of Marketing 15,000,000 33,462,500 744,611 0.02
Thomas Guiel, Chief Operations Officer 15,000,000 33,650,000 6,288,146 0.15
Ewan Hunter, Chief Data Officer 15,000,000 33,660,000 722,754 0.02
Paul Stockdale, Chief Financial Officer 15,000,000 33,980,000 6,411,252 0.15
*Shareholdings are stated following allotments pursuant to the recent
fundraising. Percentages are calculated with reference to the Company's
Enlarged Share Capital following General Admission, which is expected to take
place on 11 November 2025.
The notifications below, made in accordance with the requirements of UK Market
Abuse Regulation, provide further details:
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Alexandre Akoulitchev
2 Reason for the notification
a) Position/status Director/PDMR
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1 pence each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) 15,000,000 ordinary shares at an exercise price of 0.61 pence per share
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 10 November 2025
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name David Blum
2 Reason for the notification
a) Position/status PDMR
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1 pence each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) 15,000,000 ordinary shares at an exercise price of 0.61 pence per share
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 10 November 2025
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Thomas Guiel
2 Reason for the notification
a) Position/status PDMR
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1 pence each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) 15,000,000 ordinary shares at an exercise price of 0.61 pence per share
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 10 November 2025
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Ewan Hunter
2 Reason for the notification
a) Position/status PDMR
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1 pence each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) 15,000,000 ordinary shares at an exercise price of 0.61 pence per share
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 10 November 2025
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Iain Ross
2 Reason for the notification
a) Position/status Director/PDMR
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1 pence each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) 44,000,000 ordinary shares at an exercise price of 0.61 pence per share
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 10 November 2025
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Paul Stockdale
2 Reason for the notification
a) Position/status Director/PDMR
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1 pence each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) 15,000,000 ordinary shares at an exercise price of 0.61 pence per share
d) Aggregated information N/A
- Aggregated volume
- Price
e) Dates of the transactions 10 November 2025
f) Place of the transaction Outside a trading venue
-Ends-
For further details please contact:
Oxford BioDynamics Plc Tel: +44 (0)1865 518910
Iain Ross, Executive Chairman
Paul Stockdale, CFO
Shore Capital - Nominated Adviser and Broker Tel: +44 (0)20 7408 4090
Stephane Auton / Lucy Bowden
OAK Securities - Joint Broker Tel: +44 (0)20 3973 3678
Matthew Clarke / Tim Dainton / Calvin Man
Camarco - Financial PR Tel: +44 (0)20 3757 4980
Marc Cohen / Tilly Butcher / Fergus Young OBDFinancial@camarco.co.uk
Notes to Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.
Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
(EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
(Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.
OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.
The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6Njo3YmRiOmUxODM2ZWZhYmIxNjdhMjFiNTMxOThjNjE0YzMwYzg5YzA1MjI2MmYxMGY0ZTU1MzdjYzdlYzg1NDA5ZTcyOWU6cDpU)
, X (@OxBioDynamics) or LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHKKLFBEFLXFBB
Copyright 2019 Regulatory News Service, all rights reservedRecent news on Oxford Biodynamics
See all newsREG - Oxford BioDynamics - Preliminary Results and Notice of AGM
AnnouncementREG - Oxford BioDynamics - Notice of Results
AnnouncementREG - Oxford BioDynamics - Statement re share price, update on EpiSwitch PSE
AnnouncementREG - Oxford BioDynamics - Holding(s) in Company
AnnouncementREG - Oxford BioDynamics - Holding(s) in Company
Announcement